Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 AlteredExpression group BEFREE It should be considered in the studies that the pathological changes at the early stages of the relationship between DM and oral cancer may be related to p16 expression; however, it may also be linked with p16-related aging process. 31687322 2019
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE 91.1% of the oropharynx cancer patients had p16 positive tumors compared to 3.3% of oral cavity cancer. 29312616 2017
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 GeneticVariation group BEFREE In total, 28 loci, that is, 14q32.33 (AKT1), 5q22.2 (APC), 11q22.3 (ATM), 2q33.1 (CASP8), 11q13.3 (CCND1), 16q22.1 (CDH1), 9p21.3 (CDKN2A), 1q31.1 (COX-2), 7p11.2 (EGFR), 22q13.2 (EP300), 4q35.2 (FAT1), 4q31.3 (FBXW7), 4p16.3 (FGFR3), 1p13.3 (GSTM1-GSTT1), 11q13.2 (GSTP1), 11p15.5 (H-RAS), 3p25.3 (hOGG1), 1q32.1 (IL-10), 4q13.3 (IL-8), 12p12.1 (KRAS), 12q15 (MDM2), 12q13.12 (MLL2), 9q34.3 (NOTCH1), 17p13.1 (p53), 3q26.32 (PIK3CA), 10q23.31 (PTEN), 13q14.2 (RB1), and 5q14.2 (XRCC4), were validated to be associated with oral cancer. 29037125 2017
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE Systematic analysis revealed direct involvement of CDKN2A/p16 in oral cancer. 28939073 2017
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 PosttranslationalModification group BEFREE The aim of this study is to prospectively determine if early P16 methylation is a predictor for oral cancer development. 26137587 2015
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group CTD_human Promoter region hypermethylation and mRNA expression of MGMT and p16 genes in tissue and blood samples of human premalignant oral lesions and oral squamous cell carcinoma. 24991542 2014
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE Both pRB/p16(INK4A) and p53 are dysfunctional in many cancers, including the most common type of oral cancer, squamous cell carcinoma (OSCC) and other evidence is accumulating in support of the idea that senescence acts as a barrier to tumour development and/or progression. 21050803 2010
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 PosttranslationalModification group BEFREE Loss of p16 expression by promoter hypermethylation has been reported as an early event in the development of oral cancer. 19431196 2009
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE Our results indicate that p16(INK4A) and p14(ARF) alterations constitute a major molecular abnormality in oral cancer cases. 18268126 2008
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE The detection of CCND1 and p16 aberrations using a simple and sensitive method would be valuable for the development of effective treatment modalities for oral cancer. 17893905 2007
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE The purpose of this study is to examine the hypermethylation status of p16 and MGMT genes in both oral cancers and normal mucosa, surrounding the cancers. 16791592 2006
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE These results indicate we can use p16(INK4A) as a marker of a prognostic prediction of oral cancer and it is useful for management of OSCCs. 17052587 2006
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 PosttranslationalModification group BEFREE Thus, the detection of abnormal p16 methylation pattern may be a valuable tool for early oral cancer detection. 15492849 2004
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 AlteredExpression group BEFREE In an attempt to model oral cancer in a human cell-based system, we analyzed normal oral epithelial keratinocytes with the pRB pathway dysregulated by loss of expression of the cyclin-dependent kinase (cdk) 4/cdk6 inhibitor p16(INK4A) and/or ectopic expression of cdk4 or expression of the human papillomavirus (HPV) type 16 E7 oncoprotein. 12543805 2003
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE We can conclude that high-risk HPV types are associated with p16 overexpression, and p16 may serve as a biomarker in oral cancer related to high-risk HPV infection. 14500697 2003
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 AlteredExpression group BEFREE Our previous work showed that acquisition of immortality at the dysplasia stage of oral cancer progression was consistently associated with four changes: loss of retinoic acid receptor (RAR)-beta and p16INK4A expression, p53 mutations and activation of telomerase. 14586406 2003
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 Biomarker group BEFREE These data support that INK4a/ARF locus alterations are frequent events preceding the development of oral cancer and that p16(INK4a) inactivation occurs to a greater extent in oral dysplasia than does p14(ARF) inactivation. 12234999 2002
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 AlteredExpression group BEFREE We reported previously that acquisition of the immortal phenotype is an early event in oral cancer development (F. McGregor et al., Cancer Res., 57: 3886-3889, 1997); our current data indicate that about half of oral dysplasia cultures are immortal, and this is associated with loss of expression of retinoic acid receptor (RAR)-beta and the cell cycle inhibitor p16(ink4a) (p16), p53 mutations, and increased levels of telomerase/human telomerase reverse transcriptase mRNA. 12183435 2002
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 GeneticVariation group BEFREE Not only do Li Fraumeni patients develop second primary malignancies, but defects of the p53 pathway (p53 mutation, MDM2 over-expression, CDKN2A deletion) appear to be a ubiquitous feature of sporadic oral cancer as it occurs in the West. 11120478 2001